Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses

References

• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301 - 14; http://dx.doi.org/10.1016/S0140-6736(09)61248-4; PMID: 19586656
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al, HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161 - 70; http://dx.doi.org/10.1016/S0140-6736(07)60946-5; PMID: 17602732
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199:936 - 44; http://dx.doi.org/10.1086/597309; PMID: 19236277
   PubMed Web of Science ®Google Scholar
• Herrero R, Wacholder S, Rodríguez AC, Solomon D, González P, Kreimer AR, et al, Costa Rica Vaccine Trial Group. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011; 1:408 - 19; http://dx.doi.org/10.1158/2159-8290.CD-11-0131; PMID: 22586631
   PubMed Web of Science ®Google Scholar
• Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959 - 63; PMID: 7745754
   PubMed Web of Science ®Google Scholar
• Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995; 92:11553 - 7; http://dx.doi.org/10.1073/pnas.92.25.11553; PMID: 8524802
   PubMed Web of Science ®Google Scholar
• Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol Oncol 2010; 118:Suppl S12 - 7; http://dx.doi.org/10.1016/j.ygyno.2010.04.004; PMID: 20494219
   PubMedGoogle Scholar
• Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006; 6:231 - 43; http://dx.doi.org/10.1038/nri1783; PMID: 16498452
   PubMed Web of Science ®Google Scholar
• Roost HP, Bachmann MF, Haag A, Kalinke U, Pliska V, Hengartner H, et al. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc Natl Acad Sci U S A 1995; 92:1257 - 61; http://dx.doi.org/10.1073/pnas.92.5.1257; PMID: 7877965
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3:85ra48; http://dx.doi.org/10.1126/scitranslmed.3002336; PMID: 21632986
   PubMed Web of Science ®Google Scholar
• Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 2012; 19:1075 - 82; http://dx.doi.org/10.1128/CVI.00139-12; PMID: 22593236
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, et al, HPV-010 Study Group. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011; 7:1359 - 73; http://dx.doi.org/10.4161/hv.7.12.18282; PMID: 22048172
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011; 29:2011 - 4; http://dx.doi.org/10.1016/j.vaccine.2011.01.001; PMID: 21241731
   PubMed Web of Science ®Google Scholar
• Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007; 3:109 - 15; http://dx.doi.org/10.4161/hv.3.4.4058; PMID: 17611417
   PubMed Web of Science ®Google Scholar
• Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G, Soldan K, et al. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 2011; 29:8585 - 90; http://dx.doi.org/10.1016/j.vaccine.2011.09.021; PMID: 21939712
   PubMed Web of Science ®Google Scholar
• Herrero R, Hildesheim A, Rodríguez AC, Wacholder S, Bratti C, Solomon D, et al, Costa Rica Vaccine Trial (CVT) Group. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008; 26:4795 - 808; http://dx.doi.org/10.1016/j.vaccine.2008.07.002; PMID: 18640170
   PubMed Web of Science ®Google Scholar
• Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425 - 34; http://dx.doi.org/10.4161/hv.4.6.6912; PMID: 18948732
   PubMed Web of Science ®Google Scholar
• Kemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, Giannini SL, et al, Costa Rica Vaccine Trial (CVT) Group. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008; 26:3608 - 16; http://dx.doi.org/10.1016/j.vaccine.2008.04.074; PMID: 18541349
   PubMed Web of Science ®Google Scholar
• Dauner JG, Pan Y, Hildesheim A, Kemp TJ, Porras C, Pinto LA. Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes 2012; 26:73 - 80; http://dx.doi.org/10.1016/j.mcp.2012.01.002; PMID: 22285687
   PubMed Web of Science ®Google Scholar
• Laeyendecker O, Latimore A, Eshleman SH, Summerton J, Oliver AE, Gamiel J, et al. The effect of sample handling on cross sectional HIV incidence testing results. PLoS One 2011; 6:e25899; http://dx.doi.org/10.1371/journal.pone.0025899; PMID: 22046249
   PubMedGoogle Scholar
• Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37:2508 - 17; PMID: 10405393
   PubMed Web of Science ®Google Scholar
• van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006; 44:3292 - 8; http://dx.doi.org/10.1128/JCM.00539-06; PMID: 16954263
   PubMed Web of Science ®Google Scholar
• Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121 - 30; http://dx.doi.org/10.2307/2531248; PMID: 3719049
   PubMed Web of Science ®Google Scholar